PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23110260-3 2012 The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. alogliptin 62-72 dipeptidyl peptidase 4 Homo sapiens 4-10 22512582-0 2012 Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. alogliptin 57-67 dipeptidyl peptidase 4 Homo sapiens 22-45 22512582-3 2012 Alogliptin is a highly selective ( > 10,000-time selectivity, potent, reversible and durable serine protease dipeptidyl peptidase IV enzyme is compared to DPP-8 and DPP-9) inhibitor, which has been developed as an alternative second-line to metformin in place of a sulphonylurea. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 112-135 22512582-6 2012 The X-ray crystallography studies have been revealed that Alogliptin binds to DPP-IV active site by non-covalently and provides sustained reduction of plasma DPP-IV activity as well as lowering of blood glucose, in drug-naive patients with T2DM and inadequate glycemic control, once daily oral dosing regimen with varying levels of doses ranging from 25-800 mg. Alogliptin is approved as monotherapy and in combination with alpha-glucosidase & thiazolidinediones. alogliptin 58-68 dipeptidyl peptidase 4 Homo sapiens 78-84 22512582-6 2012 The X-ray crystallography studies have been revealed that Alogliptin binds to DPP-IV active site by non-covalently and provides sustained reduction of plasma DPP-IV activity as well as lowering of blood glucose, in drug-naive patients with T2DM and inadequate glycemic control, once daily oral dosing regimen with varying levels of doses ranging from 25-800 mg. Alogliptin is approved as monotherapy and in combination with alpha-glucosidase & thiazolidinediones. alogliptin 58-68 dipeptidyl peptidase 4 Homo sapiens 158-164 22512582-6 2012 The X-ray crystallography studies have been revealed that Alogliptin binds to DPP-IV active site by non-covalently and provides sustained reduction of plasma DPP-IV activity as well as lowering of blood glucose, in drug-naive patients with T2DM and inadequate glycemic control, once daily oral dosing regimen with varying levels of doses ranging from 25-800 mg. Alogliptin is approved as monotherapy and in combination with alpha-glucosidase & thiazolidinediones. alogliptin 362-372 dipeptidyl peptidase 4 Homo sapiens 78-84 23110260-3 2012 The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. alogliptin 62-72 dipeptidyl peptidase 4 Homo sapiens 123-129 22686547-2 2012 The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying potential selection preferences according to individual patient variables and co-morbidities. alogliptin 98-108 dipeptidyl peptidase 4 Homo sapiens 80-85 21397040-12 2011 DPP-4 inhibition by alogliptin mediates rapid vascular relaxation via GLP-1 independent, Src-Akt-eNOS mediated NO release and the activation of vascular potassium channels. alogliptin 20-30 dipeptidyl peptidase 4 Homo sapiens 0-5 21982652-2 2011 Alogliptin, a dipeptidyl peptidase 4 inhibitor, is under development for the treatment of type 2 diabetes mellitus alone or in combination with other antidiabetic therapies. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 14-36 21838055-3 2011 DPP-4 inhibitor, such as alogliptin, is already widely used in clinical practice, since there is no risks of drug-induced hypoglycemia when it is used alone. alogliptin 25-35 dipeptidyl peptidase 4 Homo sapiens 0-5 22419732-0 2012 Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. alogliptin 49-59 dipeptidyl peptidase 4 Homo sapiens 33-38 22296609-1 2012 INTRODUCTION: Alogliptin is a highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 71-93 22296609-1 2012 INTRODUCTION: Alogliptin is a highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 95-100 22296609-8 2012 EXPERT OPINION: Alogliptin is an additional choice in the group of DPP-4 inhibitors. alogliptin 16-26 dipeptidyl peptidase 4 Homo sapiens 67-72 21913883-1 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. alogliptin 102-112 dipeptidyl peptidase 4 Homo sapiens 4-26 21913883-1 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. alogliptin 102-112 dipeptidyl peptidase 4 Homo sapiens 28-33 22651127-0 2011 Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. alogliptin 61-71 dipeptidyl peptidase 4 Homo sapiens 27-50 22651127-1 2011 INTRODUCTION: Alogliptin is a pyrimidinedione-based potent and selective inhibitor of DPP IV that was discovered by Syrrx (Takeda San Diego) for the treatment of type 2 diabetes mellitus (T2D). alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 86-92 22651127-6 2011 EXPERT OPINION: Alogliptin has shown greater in vitro selectivity for DPP IV over closely related enzymes, including DPP VIII and DPP IX, in comparison with other launched DPP IV inhibitors such as sitagliptin, saxagliptin and vildagliptin. alogliptin 16-26 dipeptidyl peptidase 4 Homo sapiens 70-76 22651127-6 2011 EXPERT OPINION: Alogliptin has shown greater in vitro selectivity for DPP IV over closely related enzymes, including DPP VIII and DPP IX, in comparison with other launched DPP IV inhibitors such as sitagliptin, saxagliptin and vildagliptin. alogliptin 16-26 dipeptidyl peptidase 4 Homo sapiens 172-178 20843518-0 2010 DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 0-5 21500969-3 2011 The reader will gain detailed pharmacological and clinical information on alogliptin, dutogliptin and linagliptin and will learn how these DPP IV inhibitors may widen the whole drug class. alogliptin 74-84 dipeptidyl peptidase 4 Homo sapiens 139-145 21500969-6 2011 Preclinical and clinical studies of the novel DPP IV inhibitors alogliptin, dutogliptin and linagliptin, including published data since 2007, are presented and a comparison of these compounds is made. alogliptin 64-74 dipeptidyl peptidase 4 Homo sapiens 46-52 21595274-1 2011 Alogliptin, a dipeptidyl peptidase-4(DPP-4) inhibitor, is launched in Japan in advance of other countries in the world. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 14-36 20843518-3 2010 In this study, we used alogliptin, a specific inhibitor of DPP 4/CD26, to study the effect of DPP-4/CD26 on the activation of the extracellular signal-regulated kinase (ERK) that plays a critical role in the expression of proinflammatory cytokines and matrix metalloproteinases (MMPs) in U937 histiocytes. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 65-69 20843518-8 2010 Taken together, this study showed for the first time that the inhibition of DPP-4/CD26 by alogliptin suppressed TLR4-mediated ERK activation and ERK-dependent MMP expression by U937 cells, suggesting that DPP-4/CD26 may play an important role in macrophage-mediated inflammation response and tissue remodeling. alogliptin 90-100 dipeptidyl peptidase 4 Homo sapiens 76-81 20843518-8 2010 Taken together, this study showed for the first time that the inhibition of DPP-4/CD26 by alogliptin suppressed TLR4-mediated ERK activation and ERK-dependent MMP expression by U937 cells, suggesting that DPP-4/CD26 may play an important role in macrophage-mediated inflammation response and tissue remodeling. alogliptin 90-100 dipeptidyl peptidase 4 Homo sapiens 82-86 20843518-8 2010 Taken together, this study showed for the first time that the inhibition of DPP-4/CD26 by alogliptin suppressed TLR4-mediated ERK activation and ERK-dependent MMP expression by U937 cells, suggesting that DPP-4/CD26 may play an important role in macrophage-mediated inflammation response and tissue remodeling. alogliptin 90-100 dipeptidyl peptidase 4 Homo sapiens 205-210 20843518-8 2010 Taken together, this study showed for the first time that the inhibition of DPP-4/CD26 by alogliptin suppressed TLR4-mediated ERK activation and ERK-dependent MMP expression by U937 cells, suggesting that DPP-4/CD26 may play an important role in macrophage-mediated inflammation response and tissue remodeling. alogliptin 90-100 dipeptidyl peptidase 4 Homo sapiens 211-215 21595274-1 2011 Alogliptin, a dipeptidyl peptidase-4(DPP-4) inhibitor, is launched in Japan in advance of other countries in the world. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 37-42 21595274-2 2011 Alogliptin has high-selectivity to inhibit DPP-4 activity compared to other DPP-4 inhibitors due to its unique formula of chemical structure. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 43-48 21595274-2 2011 Alogliptin has high-selectivity to inhibit DPP-4 activity compared to other DPP-4 inhibitors due to its unique formula of chemical structure. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 76-81 21431099-4 2011 Currently, there are four DPP IV inhibitors available in various countries-alogliptin, sitagliptin, vildagliptin and saxagliptin (1). alogliptin 75-85 dipeptidyl peptidase 4 Homo sapiens 26-32 20843518-0 2010 DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 7-11 20843518-3 2010 In this study, we used alogliptin, a specific inhibitor of DPP 4/CD26, to study the effect of DPP-4/CD26 on the activation of the extracellular signal-regulated kinase (ERK) that plays a critical role in the expression of proinflammatory cytokines and matrix metalloproteinases (MMPs) in U937 histiocytes. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 59-64 20590741-5 2010 Other DPP-4 inhibitors, such as alogliptin and linagliptin, are currently in late phase of development. alogliptin 32-42 dipeptidyl peptidase 4 Homo sapiens 6-11 20859539-5 2010 Alogliptin is a new DPP-4 inhibitor that reduces glycosylated hemoglobin (HbA(1c)), is weight neutral, has an excellent safety profile, and can be used in combination with oral agents and insulin. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 20-25 20879969-8 2010 Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clinical testing to support a new drug application for the treatment of type 2 diabetes. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 41-63 20883057-1 2010 Alogliptin (Nesina ) is a dipeptidyl peptidase-4 inhibitor that is approved in Japan for the treatment of adult patients with type 2 diabetes mellitus that is inadequately controlled by diet and exercise alone or by diet plus treatment with an alpha-glucosidase inhibitor. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 26-48 20883057-1 2010 Alogliptin (Nesina ) is a dipeptidyl peptidase-4 inhibitor that is approved in Japan for the treatment of adult patients with type 2 diabetes mellitus that is inadequately controlled by diet and exercise alone or by diet plus treatment with an alpha-glucosidase inhibitor. alogliptin 12-18 dipeptidyl peptidase 4 Homo sapiens 26-48 20703380-0 2010 Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring. alogliptin 49-59 dipeptidyl peptidase 4 Homo sapiens 33-38 19650752-0 2009 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. alogliptin 60-70 dipeptidyl peptidase 4 Homo sapiens 27-49 20040339-1 2010 OBJECTIVE: The dipeptidyl peptidase-4 inhibitor alogliptin, under development for treatment of Type 2 diabetes, primarily is excreted renally. alogliptin 48-58 dipeptidyl peptidase 4 Homo sapiens 15-37 22112254-0 2009 Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. alogliptin 25-35 dipeptidyl peptidase 4 Homo sapiens 39-61 22112254-1 2009 Alogliptin is a new, potent, highly selective, orally available inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme developed for the treatment of Type 2 diabetes mellitus (T2DM). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 81-103 22112254-1 2009 Alogliptin is a new, potent, highly selective, orally available inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme developed for the treatment of Type 2 diabetes mellitus (T2DM). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 105-110 19793357-1 2009 OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, in elderly (> or =65) and younger (<65) patients with type 2 diabetes mellitus. alogliptin 50-60 dipeptidyl peptidase 4 Homo sapiens 64-86 19793357-1 2009 OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, in elderly (> or =65) and younger (<65) patients with type 2 diabetes mellitus. alogliptin 50-60 dipeptidyl peptidase 4 Homo sapiens 88-93 19622714-1 2009 Alogliptin is a dipeptidyl peptidase-4 inhibitor under investigation for treatment of patients with type 2 diabetes mellitus. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 16-38 19259628-0 2009 DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. alogliptin 57-67 dipeptidyl peptidase 4 Homo sapiens 0-4 19780719-3 2009 DPP-4 inhibitors (alogliptin, saxagliptin, sitagliptin and vildagliptin) correct the GLP-1 deficiency by blocking this degradation, prolonging the incretin effect and enhancing glucose homoeostasis. alogliptin 18-28 dipeptidyl peptidase 4 Homo sapiens 0-5 21437125-0 2009 Alogliptin: a new addition to the class of DPP-4 inhibitors. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 43-48 21437125-1 2009 BACKGROUND: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 102-124 21437125-1 2009 BACKGROUND: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 126-131 19125778-0 2009 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. alogliptin 60-70 dipeptidyl peptidase 4 Homo sapiens 27-49 19191685-0 2009 Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 36-58 19191685-1 2009 BACKGROUND: Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clinical testing to support a new drug application for the treatment of type 2 diabetes. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 53-75 19125778-1 2009 AIM: To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in combination with glyburide in patients with type 2 diabetes inadequately controlled by sulphonylurea monotherapy. alogliptin 44-54 dipeptidyl peptidase 4 Homo sapiens 86-108 19125778-1 2009 AIM: To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in combination with glyburide in patients with type 2 diabetes inadequately controlled by sulphonylurea monotherapy. alogliptin 44-54 dipeptidyl peptidase 4 Homo sapiens 110-115 18405788-1 2008 BACKGROUND: Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes (T2D). alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 69-74 19125992-0 2009 Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. alogliptin 67-77 dipeptidyl peptidase 4 Homo sapiens 34-56 19125992-1 2009 AIMS: To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase-4 inhibitor, for 26 weeks at once-daily doses of 12.5 and 25 mg in combination with metformin in patients whose HbA(1c) levels were inadequately controlled on metformin alone. alogliptin 45-55 dipeptidyl peptidase 4 Homo sapiens 63-85 18809631-0 2008 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. alogliptin 60-70 dipeptidyl peptidase 4 Homo sapiens 27-49 18809631-1 2008 OBJECTIVE: To evaluate the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin in drug-naive patients with inadequately controlled type 2 diabetes. alogliptin 68-78 dipeptidyl peptidase 4 Homo sapiens 27-49 18809631-1 2008 OBJECTIVE: To evaluate the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin in drug-naive patients with inadequately controlled type 2 diabetes. alogliptin 68-78 dipeptidyl peptidase 4 Homo sapiens 51-56 18393107-0 2008 Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 35-58 18393107-1 2008 Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. alogliptin 35-45 dipeptidyl peptidase 4 Homo sapiens 82-105 18393107-1 2008 Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. alogliptin 35-45 dipeptidyl peptidase 4 Homo sapiens 107-113 18538760-2 2008 Alogliptin potently inhibited human DPP-4 in vitro (mean IC(50), ~ 6.9 nM) and exhibited > 10,000-fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase (IC(50) > 100,000 nM). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 36-41 18538760-2 2008 Alogliptin potently inhibited human DPP-4 in vitro (mean IC(50), ~ 6.9 nM) and exhibited > 10,000-fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase (IC(50) > 100,000 nM). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 122-127 18405788-1 2008 BACKGROUND: Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes (T2D). alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 45-67 18405788-20 2008 CONCLUSIONS: In these adult patients with T2D, alogliptin inhibited plasma DPP-4 activity and significantly decreased PPG levels. alogliptin 47-57 dipeptidyl peptidase 4 Homo sapiens 75-80 18405789-0 2008 Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. alogliptin 120-130 dipeptidyl peptidase 4 Homo sapiens 87-109 18405789-1 2008 BACKGROUND: Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 45-67 18405789-1 2008 BACKGROUND: Alogliptin is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is under development for the treatment of type 2 diabetes. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 69-74 18405789-10 2008 Across alogliptin doses, mean peak DPP-4 inhibition ranged from 93% to 99%, and mean inhibition at 24 hours after dosing ranged from 74% to 97%. alogliptin 7-17 dipeptidyl peptidase 4 Homo sapiens 35-40 18405789-14 2008 CONCLUSION: In these healthy male subjects, alogliptin at single doses up to 800 mg inhibited plasma DPP-4 activity, increased active GLP-1, and was generally well tolerated, with no dose-limiting toxicity. alogliptin 44-54 dipeptidyl peptidase 4 Homo sapiens 101-106 17441705-0 2007 Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. alogliptin 13-23 dipeptidyl peptidase 4 Homo sapiens 89-112 17441705-1 2007 Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 67-90 17441705-1 2007 Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 92-97 17441705-2 2007 Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. alogliptin 67-77 dipeptidyl peptidase 4 Homo sapiens 110-115 34616361-0 2021 Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. alogliptin 51-61 dipeptidyl peptidase 4 Homo sapiens 0-23 34774622-3 2021 The critical function of glucagon-like peptide-1 (GLP-1) in neurodegenerative diseases has raised impetus in investigating the repositioning of a dipeptidyl peptidase IV inhibitor, alogliptin (ALO), as an effective treatment for PD. alogliptin 181-191 dipeptidyl peptidase 4 Homo sapiens 146-169 34287770-6 2021 A larger signal was seen for non-US Food and Drug Administration (FDA)-approved (anagliptin, vildagliptin, teneligliptin) vs FDA-approved DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin), likely because of an overestimation of the ROR for non-FDA-approved drugs. alogliptin 156-166 dipeptidyl peptidase 4 Homo sapiens 138-143 34384428-10 2021 After MCDA, the overall value orders for each DPP-4 inhibitor included Sitagliptin (0.45), Linagliptin (0.44), Vildagliptin (0.43), Alogliptin (0.42) and Saxagliptin (0.40). alogliptin 132-142 dipeptidyl peptidase 4 Homo sapiens 46-51 34484112-1 2021 Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. alogliptin 74-84 dipeptidyl peptidase 4 Homo sapiens 9-30 34484112-1 2021 Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. alogliptin 74-84 dipeptidyl peptidase 4 Homo sapiens 32-37 33850463-11 2021 The signal was significantly higher with alogliptin than with the other DPP-4 inhibitors. alogliptin 41-51 dipeptidyl peptidase 4 Homo sapiens 72-77 32809070-13 2021 While in-class switching is uncommon, saxagliptin and alogliptin are the DPP4 inhibitors most commonly switched. alogliptin 54-64 dipeptidyl peptidase 4 Homo sapiens 73-77 32317005-4 2020 RESULTS: Our study showed a favorable effect on HbA1c concentration and a slightly unfavorable effect on serum creatinine concentration in users of the five DPP-4 inhibitors, a favorable effect on lipid metabolism in sitagliptin, vildagliptin, and alogliptin users, and a favorable effect on hepatic parameters in sitagliptin, alogliptin, and linagliptin users, in comparison of the baseline and exposure periods. alogliptin 248-258 dipeptidyl peptidase 4 Homo sapiens 157-162 33441417-0 2021 Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). alogliptin 33-43 dipeptidyl peptidase 4 Homo sapiens 47-52 33441417-15 2021 CONCLUSIONS: Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting. alogliptin 13-23 dipeptidyl peptidase 4 Homo sapiens 47-52 32655736-0 2020 Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study. alogliptin 63-73 dipeptidyl peptidase 4 Homo sapiens 30-52 32655736-1 2020 Background: This study aimed to verify the safety and efficacy, including glycemic control, of the selective dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes. alogliptin 142-152 dipeptidyl peptidase 4 Homo sapiens 109-131 32493335-1 2020 BACKGROUND: The EXAMINE trial tested the efficacy and safety of alogliptin, an inhibitor of dipeptidyl peptidase 4, compared with placebo in 5380 patients with type 2 diabetes and a recent acute coronary syndrome. alogliptin 64-74 dipeptidyl peptidase 4 Homo sapiens 92-114 33952821-1 2021 Alogliptin (ALG), an inhibitor of dipeptidylpeptidase-4, is used in the management of type 2 diabetes mellitus, and has a high absorption rate (>60-71%), despite its low lipophilicity (logP=-1.4). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 34-55 33952821-1 2021 Alogliptin (ALG), an inhibitor of dipeptidylpeptidase-4, is used in the management of type 2 diabetes mellitus, and has a high absorption rate (>60-71%), despite its low lipophilicity (logP=-1.4). alogliptin 12-15 dipeptidyl peptidase 4 Homo sapiens 34-55 32588538-1 2020 Alogliptin is an antidiabetic drug that belongs to a group called dipeptidyl peptidase-4 enzyme inhibitors. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 66-88 32179246-2 2020 Alogliptin, an important selective dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes, has displayed a wide range of pharmacological capacities. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 35-57 32179246-2 2020 Alogliptin, an important selective dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes, has displayed a wide range of pharmacological capacities. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 59-64 32317005-4 2020 RESULTS: Our study showed a favorable effect on HbA1c concentration and a slightly unfavorable effect on serum creatinine concentration in users of the five DPP-4 inhibitors, a favorable effect on lipid metabolism in sitagliptin, vildagliptin, and alogliptin users, and a favorable effect on hepatic parameters in sitagliptin, alogliptin, and linagliptin users, in comparison of the baseline and exposure periods. alogliptin 327-337 dipeptidyl peptidase 4 Homo sapiens 157-162 31264097-2 2019 We aimed to determine whether or not "within class" switching to alogliptin, the DPP-4 inhibitor with lowest acquisition cost, is a clinically appropriate strategy. alogliptin 65-75 dipeptidyl peptidase 4 Homo sapiens 81-86 31654243-1 2019 The dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM), including the USA, Europe, and Japan. alogliptin 46-56 dipeptidyl peptidase 4 Homo sapiens 4-26 30156056-1 2019 AIMS/INTRODUCTION: The aim of the present study was to investigate the effects of metformin and a dipeptidyl peptidase-4 inhibitor, alogliptin, on body composition in a 12-week randomized add-on trial in Japanese participants with type 2 diabetes. alogliptin 132-142 dipeptidyl peptidase 4 Homo sapiens 98-120 31018682-2 2019 The large trials evaluating the dipeptidyl peptidase-4 inhibitors sitagliptin, alogliptin and saxagliptin demonstrated safety for cardiovascular disease. alogliptin 79-89 dipeptidyl peptidase 4 Homo sapiens 32-54 31045223-0 2019 Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus. alogliptin 48-58 dipeptidyl peptidase 4 Homo sapiens 15-37 31275243-8 2019 Five of the DPP-4 inhibitors (sitagliptin, vildagliptin, alogliptin, saxagliptin and linagliptin) were approved by regulatory authorities and entered the market between 2006 and 2013. alogliptin 57-67 dipeptidyl peptidase 4 Homo sapiens 12-17 32734188-1 2019 Alogliptin is one of the dipeptidyl peptidase-4 inhibitors used to treat patients with type 2 diabetes. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 25-47 30654307-4 2019 In the current study, we investigated whether the DPP-4 inhibitor alogliptin could prevent degradation of the articular extracellular matrix in human primary chondrocytes. alogliptin 66-76 dipeptidyl peptidase 4 Homo sapiens 50-55 30242726-1 2019 AIMS: The aim is to evaluate the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4-I: sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin) in patients with type 2 diabetes. alogliptin 155-165 dipeptidyl peptidase 4 Homo sapiens 56-78 30654307-7 2019 This suggests that DPP-4 inhibitors such as alogliptin may be used as an effective preventative therapy against continued destruction of the articular extracellular matrix in OA. alogliptin 44-54 dipeptidyl peptidase 4 Homo sapiens 19-24 30318179-8 2019 Unlike other DPP-4 inhibitors, sitagliptin and alogliptin are mainly excreted in the urine and suppress renal sodium-hydrogen exchanger 3 activity. alogliptin 47-57 dipeptidyl peptidase 4 Homo sapiens 13-18 30701000-1 2019 Background: One of the treatment options for type 2 diabetes mellitus (DM) is a combination drug (CD) that contains the dipeptidyl peptidase-4 inhibitor (DPP4I) alogliptin (AG) together with pioglitazone (PG). alogliptin 161-171 dipeptidyl peptidase 4 Homo sapiens 120-142 33693068-5 2018 Cardiovascular outcome trials conducted so far suggest that DPP-4 inhibitors (sitagliptin, alogliptin, and saxagliptin) do not promote arteriosclerotic disease, but there may be a difference between these drugs with regard to safety for heart failure. alogliptin 91-101 dipeptidyl peptidase 4 Homo sapiens 60-65 29581078-9 2018 CONCLUSIONS: Addition of the dipeptidyl peptidase-4 inhibitor alogliptin to dual therapy with metformin plus sulfonylurea significantly reduced HbA1c and was well tolerated. alogliptin 62-72 dipeptidyl peptidase 4 Homo sapiens 29-51 30345140-1 2018 Alogliptin benzoate, a member of dipeptidyl peptidase-4 inhibitors, is a recent drug developed by Takeda Pharmaceutical Company for the treatment of Type 2 diabetes; it potentiates the effect of incretin hormones through the inhibition of their degradation. alogliptin 0-19 dipeptidyl peptidase 4 Homo sapiens 33-55 29652078-1 2018 Alogliptin, a dipeptidyl peptidase-4 inhibitor, is approved for the treatment of patients with type 2 diabetes (T2DM). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 14-36 29679391-2 2018 In addition to anti-diabetic effects, the five most widely used DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) also exert cardiovascular protective effects. alogliptin 138-148 dipeptidyl peptidase 4 Homo sapiens 64-69 29359260-8 2018 DPP-4 inhibitors have a controversial effect: saxagliptin and alogliptin may increase the risk of HF as opposed to vildagliptin and sitagliptin. alogliptin 62-72 dipeptidyl peptidase 4 Homo sapiens 0-5 29769203-10 2018 DPP-IV inhibition with alogliptin appears to be safe even in the high-risk period following an ACS. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 0-6 29270818-6 2018 Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. alogliptin 157-167 dipeptidyl peptidase 4 Homo sapiens 53-75 29270818-6 2018 Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. alogliptin 157-167 dipeptidyl peptidase 4 Homo sapiens 77-82 28323503-0 2017 Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved beta-cell function and insulin sensitivity in metformin treated PCOS. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 7-12 29330812-2 2018 The present study evaluated the effect of alogliptin, a dipeptidyl peptidase-4 inhibitor, on the longitudinal change in GSM, an index of the tissue characteristics of the carotid wall, in patients with type 2 diabetes (T2DM). alogliptin 42-52 dipeptidyl peptidase 4 Homo sapiens 56-78 29264712-1 2018 INTRODUCTION: Alogliptin is a highly selective, potent, and orally available dipeptidyl peptidase-4 (DPP-4) inhibitor. alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 77-99 29264712-1 2018 INTRODUCTION: Alogliptin is a highly selective, potent, and orally available dipeptidyl peptidase-4 (DPP-4) inhibitor. alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 101-106 28323503-2 2017 The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves beta-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR. alogliptin 86-96 dipeptidyl peptidase 4 Homo sapiens 45-67 28323503-2 2017 The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves beta-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR. alogliptin 86-96 dipeptidyl peptidase 4 Homo sapiens 69-74 28323503-2 2017 The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves beta-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR. alogliptin 98-101 dipeptidyl peptidase 4 Homo sapiens 45-67 28323503-2 2017 The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves beta-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR. alogliptin 98-101 dipeptidyl peptidase 4 Homo sapiens 69-74 28275958-1 2017 INTRODUCTION: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), approved for the treatment of type 2 diabetes mellitus (T2DM). alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 104-126 28275958-1 2017 INTRODUCTION: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), approved for the treatment of type 2 diabetes mellitus (T2DM). alogliptin 14-24 dipeptidyl peptidase 4 Homo sapiens 128-133 28275958-9 2017 All analyses over all trial population sets produced very similar results, and show that alogliptin 25 mg is as least as effective (as measured by change in HbA1c from baseline, but supported by other outcome measures: change in body weight and FPG from baseline) and safe (as measured by incidence of hypoglycemia and adverse events leading to study discontinuation) as all the other DPP-4 inhibitors in triple therapy. alogliptin 89-99 dipeptidyl peptidase 4 Homo sapiens 385-390 27236239-7 2017 Therefore, this study will be performed to evaluate the effects of alogliptin, a DPP-4 inhibitor, on coronary atherosclerosis using FFRCT in patients with type 2 diabetes. alogliptin 67-77 dipeptidyl peptidase 4 Homo sapiens 81-86 27999883-1 2017 PURPOSE: The aim of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of a single 12.5- or 25-mg dose of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in pediatric (children and adolescents) and adult subjects with type 2 diabetes mellitus (T2DM). alogliptin 134-144 dipeptidyl peptidase 4 Homo sapiens 172-177 27999883-11 2017 CONCLUSIONS: A 25-mg dose of alogliptin in pediatric subjects achieved alogliptin exposures and DPP-4 inhibition similar to those in adult T2DM patients without safety concerns; therefore, this dose is recommended for a pediatric phase 3 trial. alogliptin 29-39 dipeptidyl peptidase 4 Homo sapiens 96-101 28932239-2 2017 Commercially available gliptin-based drugs such as sitagliptin, anagliptin, linagliptin, saxagliptin, and alogliptin were specifically developed as DPPIV inhibitors for diabetic patients. alogliptin 106-116 dipeptidyl peptidase 4 Homo sapiens 148-153 30603324-2 2017 In this study, we investigated the effects of alogliptin, a DPP-4 inhibitor, on the GA/HbA1c ratio in patients with type 2 diabetes mellitus. alogliptin 46-56 dipeptidyl peptidase 4 Homo sapiens 60-65 28804210-3 2017 Here we report a case of a pediatric patient with MODY1 who was successfully treated with a DPP-4 inhibitor, alogliptin. alogliptin 109-119 dipeptidyl peptidase 4 Homo sapiens 92-97 27190600-2 2016 Taking advantage of X-ray cocrystal structures of sitagliptin and other DPP-4 inhibitors, such as alogliptin and linagliptin bound to DPP-4, and aided by molecular modeling, we designed several series of heterocyclic compounds as initial targets. alogliptin 98-108 dipeptidyl peptidase 4 Homo sapiens 72-77 27832184-2 2016 We studied the interaction between DPP-4 and its inhibitor drugs (sitagliptin 1, linagliptin 2, alogliptin 3, and teneligliptin 4) quantitatively by using fragment molecular orbital calculations at the RI-MP2/cc-pVDZ level to analyze the inhibitory activities of the drugs. alogliptin 96-106 dipeptidyl peptidase 4 Homo sapiens 35-40 27573605-0 2016 Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease. alogliptin 23-33 dipeptidyl peptidase 4 Homo sapiens 14-19 27573605-1 2016 BACKGROUND: The present study determined whether dipeptidyl peptidase-4 (DPP-4) inhibition by alogliptin improves coronary flow reserve (CFR) and left ventricular election fraction (LVEF) in patients with type 2 DM and CAD. alogliptin 94-104 dipeptidyl peptidase 4 Homo sapiens 49-71 27573605-1 2016 BACKGROUND: The present study determined whether dipeptidyl peptidase-4 (DPP-4) inhibition by alogliptin improves coronary flow reserve (CFR) and left ventricular election fraction (LVEF) in patients with type 2 DM and CAD. alogliptin 94-104 dipeptidyl peptidase 4 Homo sapiens 73-78 27573605-9 2016 CONCLUSION: The inhibition of DPP-4 by alogliptin improved CFR and LVEF evaluated by MRI in patients with type 2 DM and CAD and the improvement in CFR was associated with increased LV systolic function. alogliptin 39-49 dipeptidyl peptidase 4 Homo sapiens 30-35 27480840-0 2016 Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. alogliptin 156-166 dipeptidyl peptidase 4 Homo sapiens 123-145 27480840-3 2016 Patients with type 2 diabetes mellitus and a recent acute coronary syndrome were randomly assigned to receive the dipeptidyl peptidase 4 inhibitor alogliptin or placebo added to existing antihyperglycemic and cardiovascular prophylactic therapies. alogliptin 147-157 dipeptidyl peptidase 4 Homo sapiens 114-136 26824365-7 2016 Dipeptidyl peptidase-IV inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) are not inferior to sulfonylureas, causing significantly less hypoglycaemia and not inducing weight gain. alogliptin 36-46 dipeptidyl peptidase 4 Homo sapiens 0-23 26628419-0 2016 Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 14-36 26125284-0 2016 The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes. alogliptin 46-56 dipeptidyl peptidase 4 Homo sapiens 30-35 26125284-4 2016 In the present study, we investigated (1) the effect of the DPP-4 inhibitor alogliptin on HbA1c, blood glucose (BG), and serum lipid in Japanese patients with type 2 diabetes, (2) the relationship between the HbA1c levels at baseline and the effects of alogliptin, and (3) the effects of switching of the DPP-4 inhibitor to alogliptin after 12 months" administration of sitagliptin on glycemic control and serum lipids. alogliptin 76-86 dipeptidyl peptidase 4 Homo sapiens 60-65 26607297-1 2016 INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors such as alogliptin are becoming more widely established as treatment options for patients with type 2 diabetes (T2DM) because of their ability to improve glycemic control without increasing the risk of hypoglycemia or weight gain. alogliptin 64-74 dipeptidyl peptidase 4 Homo sapiens 14-36 26607297-1 2016 INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors such as alogliptin are becoming more widely established as treatment options for patients with type 2 diabetes (T2DM) because of their ability to improve glycemic control without increasing the risk of hypoglycemia or weight gain. alogliptin 64-74 dipeptidyl peptidase 4 Homo sapiens 38-43 26218204-0 2015 An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. alogliptin 79-89 dipeptidyl peptidase 4 Homo sapiens 46-68 26218204-1 2015 Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that is a class of relatively new oral hypoglycaemic drugs used in patients with type 2 diabetes (T2DM), can be used as monotherapy or in combination with other anti-diabetic agents, including metformin, pioglitazone, sulfonylureas and insulin with a considerable therapeutic effect. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 14-36 26218204-1 2015 Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that is a class of relatively new oral hypoglycaemic drugs used in patients with type 2 diabetes (T2DM), can be used as monotherapy or in combination with other anti-diabetic agents, including metformin, pioglitazone, sulfonylureas and insulin with a considerable therapeutic effect. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 38-43 26962605-8 2015 Alogliptin is the fourth DPP-4 inhibitor to be introduced in Canada after sitagliptin, saxagliptin, and linagliptin. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 25-30 26962596-7 2015 Alogliptin is the fourth DPP-4 inhibitor to be introduced in Canada after sitagliptin, saxagliptin, and linagliptin. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 25-30 25765696-1 2015 BACKGROUND: The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and recent acute coronary syndromes. alogliptin 76-86 dipeptidyl peptidase 4 Homo sapiens 60-65 26103461-3 2015 An efficient approach for the synthesis of the intermediate of the orally administered anti-diabetic drugs Alogliptin and Linagliptin in the DPP-4 inhibitor class was also developed. alogliptin 107-117 dipeptidyl peptidase 4 Homo sapiens 141-146 26089691-5 2015 The DPP-4 class was modeled with a meta-analysis of HbA1c and weight change, pooling results from published trials of alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin. alogliptin 118-128 dipeptidyl peptidase 4 Homo sapiens 4-9 25936384-2 2015 A unique fixed-dose combination combines a thiazolidinedione (pioglitazone) and a dipeptidyl peptidase-4 inhibitor (alogliptin). alogliptin 116-126 dipeptidyl peptidase 4 Homo sapiens 82-104 25914541-4 2015 Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. alogliptin 0-19 dipeptidyl peptidase 4 Homo sapiens 59-64 25855222-1 2015 The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina , Vipidia ) is approved in numerous countries worldwide for the treatment of type 2 diabetes mellitus. alogliptin 37-47 dipeptidyl peptidase 4 Homo sapiens 4-26 25914541-5 2015 Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. alogliptin 29-39 dipeptidyl peptidase 4 Homo sapiens 202-207 25678772-3 2015 Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its great antihyperglycemia effect in T2DM patients. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 41-63 24532820-1 2015 PURPOSE: Alogliptin is the newest dipeptidyl peptidase 4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes either alone or in combination with other antidiabetic agents. alogliptin 9-19 dipeptidyl peptidase 4 Homo sapiens 34-56 24532820-1 2015 PURPOSE: Alogliptin is the newest dipeptidyl peptidase 4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes either alone or in combination with other antidiabetic agents. alogliptin 9-19 dipeptidyl peptidase 4 Homo sapiens 58-63 24532820-3 2015 SUMMARY: As a DPP-4 inhibitor, alogliptin raises postprandial levels of glucagon-like peptide 1, leading to insulin secretion and glucose homeostasis. alogliptin 31-41 dipeptidyl peptidase 4 Homo sapiens 14-19 24532820-10 2015 The efficacy profile of alogliptin is comparable to other DPP-4 inhibitors. alogliptin 24-34 dipeptidyl peptidase 4 Homo sapiens 58-63 25331711-4 2015 Most DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin) are predominantly excreted by the kidneys. alogliptin 63-73 dipeptidyl peptidase 4 Homo sapiens 5-10 25283263-3 2014 Results of randomized prospective multicenter trials with the DPP-4 inhibitors alogliptin and vildagliptin have in fact generated new uncertainties and clearly not totally excluded the possibility of a class side effect. alogliptin 79-89 dipeptidyl peptidase 4 Homo sapiens 62-67 27200603-0 2014 Assessment of The Economic Value Of Dpp-4 Inhibitor Alogliptin Compared With Sitagliptin, Saxagliptin, And Linagliptin. alogliptin 52-62 dipeptidyl peptidase 4 Homo sapiens 36-41 24552466-5 2014 The patient was treated with a dipeptidyl peptidase-4 (DPP4) inhibitor, alogliptin, at a dose of 25 mg per day. alogliptin 72-82 dipeptidyl peptidase 4 Homo sapiens 31-53 24552466-5 2014 The patient was treated with a dipeptidyl peptidase-4 (DPP4) inhibitor, alogliptin, at a dose of 25 mg per day. alogliptin 72-82 dipeptidyl peptidase 4 Homo sapiens 55-59 25424968-2 2014 The aim of this study was to evaluate the benefits of the dipeptidyl peptidase-4 inhibitor, alogliptin, versus glipizide, a sulfonylurea, in achieving glycemic control without the risk of hypoglycemia, weight gain, or both in older patients with T2DM. alogliptin 92-102 dipeptidyl peptidase 4 Homo sapiens 58-80 30736193-4 2014 This article summarizes the pharmacological and pharmacokinetic properties of alogliptin, a dipeptidyl peptidase-4 inhibitor, and also evaluates its clinical efficacy, safety and tolerability in the treatment of patients with Type 2 diabetes. alogliptin 78-88 dipeptidyl peptidase 4 Homo sapiens 92-114 24996141-0 2014 Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. alogliptin 95-105 dipeptidyl peptidase 4 Homo sapiens 27-32 24585460-1 2014 The single enantiomer drug, alogliptin (Alo, Nesina ) is a novel, orally available and selective dipeptidyl peptidase-4 inhibitor used for the treatment of type II diabetes. alogliptin 40-43 dipeptidyl peptidase 4 Homo sapiens 97-119 24585460-1 2014 The single enantiomer drug, alogliptin (Alo, Nesina ) is a novel, orally available and selective dipeptidyl peptidase-4 inhibitor used for the treatment of type II diabetes. alogliptin 45-51 dipeptidyl peptidase 4 Homo sapiens 97-119 24585460-1 2014 The single enantiomer drug, alogliptin (Alo, Nesina ) is a novel, orally available and selective dipeptidyl peptidase-4 inhibitor used for the treatment of type II diabetes. alogliptin 28-38 dipeptidyl peptidase 4 Homo sapiens 97-119 25227623-1 2014 INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4. alogliptin 66-76 dipeptidyl peptidase 4 Homo sapiens 14-36 25227623-1 2014 INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4. alogliptin 66-76 dipeptidyl peptidase 4 Homo sapiens 38-43 25227623-1 2014 INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4. alogliptin 66-76 dipeptidyl peptidase 4 Homo sapiens 294-299 25171159-2 2014 In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D. alogliptin 115-125 dipeptidyl peptidase 4 Homo sapiens 15-37 24996141-1 2014 Highly potent DPP-4 inhibitors have been identified by hybrid compound design based on linagliptin and alogliptin. alogliptin 103-113 dipeptidyl peptidase 4 Homo sapiens 14-19 24646052-7 2014 EXPERT OPINION: Alogliptin is a DPP-4 inhibitor that can help in improving glycemic control in patients with type 2 diabetes, including the elderly. alogliptin 16-26 dipeptidyl peptidase 4 Homo sapiens 32-37 24400655-1 2014 AIM: To evaluate the efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin plus metformin (A + M) initial combination therapy versus either as monotherapy in drug-naive T2DM patients. alogliptin 81-91 dipeptidyl peptidase 4 Homo sapiens 48-70 25158388-0 2014 [Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety]. alogliptin 1-11 dipeptidyl peptidase 4 Homo sapiens 35-40 25158388-1 2014 Alogliptin (Vipidia) is a new selective inhibitor of dipeptidyl peptidase-4. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 53-75 24717767-7 2014 DPP-4 inhibitor alogliptin was administered for steroid diabetes. alogliptin 16-26 dipeptidyl peptidase 4 Homo sapiens 0-5 25050071-1 2014 Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 26-48 24285765-5 2013 DATA SYNTHESIS: Alogliptin is a highly selective and potent competitive inhibitor of DPP-4. alogliptin 16-26 dipeptidyl peptidase 4 Homo sapiens 85-90 24993124-0 2014 Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 30-52 24993124-0 2014 Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 54-59 24993124-4 2014 Since 2013, alogliptin is the 4(th) approved DPP-4 inhibitor available on the market. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 45-50 24376359-3 2013 The study goal was to determine the efficacy of alogliptin, a DPP-4 inhibitor, to enhance human beta cell function and proliferation in an in vivo context using diabetic immunodeficient mice engrafted with human pancreatic islets. alogliptin 48-58 dipeptidyl peptidase 4 Homo sapiens 62-67 23861159-0 2013 Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 26-48 24375601-2 2014 SUMMARY: Alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4). alogliptin 9-19 dipeptidyl peptidase 4 Homo sapiens 95-117 24375601-2 2014 SUMMARY: Alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4). alogliptin 9-19 dipeptidyl peptidase 4 Homo sapiens 119-124 24375601-9 2014 Alogliptin selectively binds to and inhibits DPP-4 in vitro at concentrations approximating therapeutic exposures. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 45-50 24375601-11 2014 As with the other DPP-4 inhibitors, use of alogliptin may be associated with the development of pancreatitis during therapy. alogliptin 43-53 dipeptidyl peptidase 4 Homo sapiens 18-23 24375601-12 2014 CONCLUSION: Alogliptin, a selective DPP-4 inhibitor, does not differ greatly from the other DPP-4 inhibitors currently available. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 36-41 24225429-0 2014 DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy. alogliptin 22-32 dipeptidyl peptidase 4 Homo sapiens 0-5 24225429-2 2014 To elucidate whether treatment with stronger DPP-4 inhibitor on top of angiotensin II type 1 receptor blocker (ARB) provides greater renal protective effects, we performed a crossover study with two DPP-4 inhibitors, sitagliptin and alogliptin, in twelve type 2 diabetic patients with incipient nephropathy taking ARBs. alogliptin 233-243 dipeptidyl peptidase 4 Homo sapiens 45-50 25185672-1 2014 The main purpose of the current study was to investigate the effect of a combination of alogliptin [a dipeptydil peptidase (DPP)-4 inhibitor] and lansoprazole [a proton pump inhibitor (PPI)] compared with alogliptin mono-therapy on glycemic control in patients with type 2 diabetes. alogliptin 88-98 dipeptidyl peptidase 4 Homo sapiens 102-130 24285765-1 2013 OBJECTIVE: To review the pharmacology, pharmacokinetics, safety, and efficacy of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor in the management of type 2 diabetes mellitus (T2DM). alogliptin 81-91 dipeptidyl peptidase 4 Homo sapiens 95-117 24285765-1 2013 OBJECTIVE: To review the pharmacology, pharmacokinetics, safety, and efficacy of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor in the management of type 2 diabetes mellitus (T2DM). alogliptin 81-91 dipeptidyl peptidase 4 Homo sapiens 119-124 23994324-1 2013 The superposition of the DPP-IV complex revealed that the butynyl group of Linagliptin can be freely switched with the cyanobenzyl group of Alogliptin. alogliptin 140-150 dipeptidyl peptidase 4 Homo sapiens 25-31 23992602-2 2013 We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. alogliptin 41-51 dipeptidyl peptidase 4 Homo sapiens 72-94 23992602-2 2013 We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. alogliptin 41-51 dipeptidyl peptidase 4 Homo sapiens 96-101 23994324-2 2013 Thus, a pharmacophore hybridization of Alogliptin was initiated and led to a novel DPP-IV inhibitor, 11a. alogliptin 39-49 dipeptidyl peptidase 4 Homo sapiens 83-89 23994324-4 2013 A novel series of potent DPP-IV inhibitors represented by compound 11m (IC50=0.4 nM) was ultimately obtained with a robust pharmacokinetic profile and superior in vitro and in vivo efficacy compared to Alogliptin. alogliptin 202-212 dipeptidyl peptidase 4 Homo sapiens 25-31 23489301-1 2013 AIM: As there have been concerns that some classes or agents for the treatment of type 2 diabetes may increase CV risk, we evaluated the cardiovascular profile of the dipeptidyl peptidase-4 inhibitor alogliptin. alogliptin 200-210 dipeptidyl peptidase 4 Homo sapiens 167-189 24068868-0 2013 Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. alogliptin 71-81 dipeptidyl peptidase 4 Homo sapiens 0-22 24068868-5 2013 The five available DPP-4 inhibitors, also known as "gliptins" (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. alogliptin 116-126 dipeptidyl peptidase 4 Homo sapiens 19-24 23707531-5 2013 Five different DPP-4 inhibitors, often called as "gliptins", namely sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin have been approved hitherto for clinical use. alogliptin 124-134 dipeptidyl peptidase 4 Homo sapiens 15-20 23602966-0 2013 Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. alogliptin 0-10 dipeptidyl peptidase 4 Homo sapiens 14-35 23602966-3 2013 Alogliptin benzoate (AGL), a selective inhibitor of dipeptidylpeptidase-4 (DPP-4) functioning as a long-acting agonist of GLP-1, is in clinical use worldwide for patients with diabetes mellitus type 2. alogliptin 0-19 dipeptidyl peptidase 4 Homo sapiens 52-73 23602966-3 2013 Alogliptin benzoate (AGL), a selective inhibitor of dipeptidylpeptidase-4 (DPP-4) functioning as a long-acting agonist of GLP-1, is in clinical use worldwide for patients with diabetes mellitus type 2. alogliptin 0-19 dipeptidyl peptidase 4 Homo sapiens 75-80 23602966-3 2013 Alogliptin benzoate (AGL), a selective inhibitor of dipeptidylpeptidase-4 (DPP-4) functioning as a long-acting agonist of GLP-1, is in clinical use worldwide for patients with diabetes mellitus type 2. alogliptin 21-24 dipeptidyl peptidase 4 Homo sapiens 52-73 23602966-3 2013 Alogliptin benzoate (AGL), a selective inhibitor of dipeptidylpeptidase-4 (DPP-4) functioning as a long-acting agonist of GLP-1, is in clinical use worldwide for patients with diabetes mellitus type 2. alogliptin 21-24 dipeptidyl peptidase 4 Homo sapiens 75-80 23323612-3 2013 CASE REPORT: We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. alogliptin 129-139 dipeptidyl peptidase 4 Homo sapiens 112-117 23600363-0 2013 Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with alpha-glucosidase inhibitors. alogliptin 72-82 dipeptidyl peptidase 4 Homo sapiens 39-61 23452780-1 2013 BACKGROUND: Alogliptin is a new dipeptidyl peptidase (DPP-4) inhibitor, which is under investigation for treatment of type 2 diabetes either alone or in combination with other antidiabetic drugs. alogliptin 12-22 dipeptidyl peptidase 4 Homo sapiens 54-59 23965491-1 2013 AIM: Alogliptin, an efficacious inhibitor of DPP-4 that improves glycemic control, as well as the pancreatic beta-cell function, is now increasingly used to accomplish glycemic targets in type 2 diabetic patients. alogliptin 5-15 dipeptidyl peptidase 4 Homo sapiens 45-50 23289982-0 2013 The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. alogliptin 37-47 dipeptidyl peptidase 4 Homo sapiens 4-26 23289982-1 2013 OBJECTIVES: The potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin improves glycemic control in patients with type 2 diabetes through incretin hormone-mediated increases in both alpha- and beta-cell responsiveness to glucose. alogliptin 78-88 dipeptidyl peptidase 4 Homo sapiens 37-59 23289982-1 2013 OBJECTIVES: The potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin improves glycemic control in patients with type 2 diabetes through incretin hormone-mediated increases in both alpha- and beta-cell responsiveness to glucose. alogliptin 78-88 dipeptidyl peptidase 4 Homo sapiens 61-66 23525426-3 2013 We therefore hypothesized that DPP-4 inhibitors (DPP-4Is) improve endothelial function in T2DM patients and performed 2 prospective, randomized crossover trials to compare the DPP-4I sitagliptin and an alpha-glucosidase inhibitor, voglibose (in study 1) and the DPP-4Is sitagliptin and alogliptin (in study 2). alogliptin 286-296 dipeptidyl peptidase 4 Homo sapiens 31-36 23298374-2 2013 We investigated the postprandial effects of a dipeptidyl peptidase IV inhibitor, alogliptin, on endothelial dysfunction and the lipid profile. alogliptin 81-91 dipeptidyl peptidase 4 Homo sapiens 46-69